{"name":"Recardio, Inc.","slug":"recardio-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Dutogliptin + Filgrastim","genericName":"Dutogliptin + Filgrastim","slug":"dutogliptin-filgrastim","indication":"Heart failure with reduced ejection fraction (HFrEF) with glycemic control","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Filgrastim Injectable Product","genericName":"Filgrastim Injectable Product","slug":"filgrastim-injectable-product","indication":"Neutropenia","status":"phase_2"}]}],"pipeline":[{"name":"Dutogliptin + Filgrastim","genericName":"Dutogliptin + Filgrastim","slug":"dutogliptin-filgrastim","phase":"phase_3","mechanism":"Dutogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to enhance incretin signaling and improve glycemic control, while filgrastim stimulates granulocyte colony-stimulating factor (G-CSF) receptors to promote bone marrow recovery and cardiac regeneration.","indications":["Heart failure with reduced ejection fraction (HFrEF) with glycemic control","Post-myocardial infarction cardiac dysfunction"],"catalyst":""},{"name":"Filgrastim Injectable Product","genericName":"Filgrastim Injectable Product","slug":"filgrastim-injectable-product","phase":"phase_2","mechanism":"Stimulates the production of white blood cells by binding to and activating the G-CSF receptor.","indications":["Neutropenia","Febrile neutropenia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQZWQwTjRBcTI1Qk5LZFd3dVZ5VEZIdFRNc1hCSWhhcjdiVmR3WWNuNy1oUEhHaXdXQUYwR0VJSVRWVENZT3Z0QU1uOGdHaVd3UlBwaWpERGpGRS1Ba0l0U2xPcDA3WWs3UVp3RmZQV2RfblBMQTBxQVgwaGhnbU1KY3dJQVNmSGZXZ2p2R2RXZWM0b0lVUTBKQWdRc2JWSzBNWHY0TnVqR1VpSW100gG0AUFVX3lxTE5XSUFZU19pajd2SVg1U2FSaWhCejNqWjY2a1BaV3dwWS1rMDYzMkNhYld0RXA2aDA3NUtEMmZuUWZTSWhIYnRWZ1NYV2dITmpWUDZZbkFzUDlQaHpGYUduYjJxSEU4VXp6cE5SR3dxc1RtSzNqQXJ1aWVqeldHRmhZM3hIM1JsbHlUWFIyOTg0UlJULWFDMG01M1BCTTZuRXFDT2s3bDJuLWFRaWRYMG5aeE1HMA?oc=5","date":"2026-02-03","type":"pipeline","source":"Insider Monkey","summary":"Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory - Insider Monkey","headline":"Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFBlV0ZhM19aRlFyZFp6RURpdWNyVDVfRDkzRDNncGl5NXFGZ2lZQ2lndE5ILXhRNzJiZ293ZXl4NFRaVklWbDI4Z2hBcFMwVjNZcW1IOThxcmJvT3k0R2NQeXpDOHk5andYYkZ4OS1ZcXIzcDlXeTRLUlJuMzNZZw?oc=5","date":"2026-01-29","type":"deal","source":"SeeNews","summary":"Serbia's Galenika buys Slovenia's Sanofarm - SeeNews","headline":"Serbia's Galenika buys Slovenia's Sanofarm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQcXBnT3lSVkZva19NelpKdEV6UEdQekg4N2hNeG03ODhHSEF0T2s5NmtFRDFjT040eGRlQllOVVRmRHFqNmJtS0c1QjYyOHJsVE1qdTMwVUk1OUQ5VEJyaWdyRjlfeHRTWTBIS1RMNGI0TmYxeXZFNGl1dnJUbTFBXzFjbnF5NTjSAY8BQVVfeXFMTUNzc3BLbXNXQ1hDWWlwZkxzbk9UcEZ5MjFSOXBGbkZzcWhTbklDTGpFV0p0dWh3VXo0SmVObHl2ZVQ5NUg1SFc4Y1ZLUTRTMUtGTURZSllIY3JJZWRvM3puaEIzdlVrTjQ3WVQtZHFSUklFRjFQd1lBQkdDOC14cEVGSXYxNmpxZmUwWjdmbXc?oc=5","date":"2026-01-15","type":"pipeline","source":"Insider Monkey","summary":"Harrow, Inc. (HROW): A Bull Case Theory - Insider Monkey","headline":"Harrow, Inc. (HROW): A Bull Case Theory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxObkZSaVlOTDJpT1RWUEZTclI4QU5lWEFFcVlmZ2NKZTR1d0RBNDkwZVF0cDBHMEZEczUzcVU4eTg4c3RnZkwtTzlnZWJWb3lubnRtSF9pd1FqZFlDNHI0Sktld3ZhakY3aVBQWGNqRThkYWMxdXNvaEtDcTRNWF8tNjBsLTlfTXBvZzJoZkpMYzZLVnlyTGYwTTNVN3p2aTNZX2NlNXhiME1aX1BQZm1GS2NKYXNuOEVvcTF0ZDBYU2RYNnVRekxUcw?oc=5","date":"2026-01-08","type":"pipeline","source":"prnewswire.com","summary":"Cumulus Neuroscience Appoints Ricardo Sáinz Fuertes, MD as New Board Chair - prnewswire.com","headline":"Cumulus Neuroscience Appoints Ricardo Sáinz Fuertes, MD as New Board Chair","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOUHBlMDJlQ0RKcm1QWTNjODhGdTNmc2dZNC1TNDZwTFNVME1vVHdRS2tYN1JXTUlIbzRNS1dnWnpKTG9MVzliS0hFZkMzT3R5Mm1QUUt0Y3ZTSURteFExZ3UxaEVTMHhHTG5GMGVNSDZBVzFqWTJ3M3NsckZWZl81cFR0Wm9id9IBjgFBVV95cUxOZE5zZVZiTElKMmZ3RDZUdzBRbzRHOEkzU1E1cUQzcmdvWkNIc1N6WFZjckk5QTBQelk5dUgybWRzSUpqenpSWXJtMjR4NDVtT0t6VjRpek56N1JsTXNUTUZUY2wzejJKVl9EUGV3cTY5ZzYyMk1WVzNoU1lLSlF3ZFpsb2dTMjJxOFdyM1hR?oc=5","date":"2025-12-04","type":"pipeline","source":"Insider Monkey","summary":"Pfizer Inc. (PFE): A Bull Case Theory - Insider Monkey","headline":"Pfizer Inc. (PFE): A Bull Case Theory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQZGhtZW13V3M5aHJnQkpjTFdETXhJdXdsSFZOMWlfR2lNcXZvYkxEakNmQ1k5a0tNd0cxbm5oMllwakFxWEp3WEJlOGFoblFienlQbGl5Z096TFREWGtvS1ItVEVnQTV0cHVmMnZKa1g5MTd3UUFyQVgzdUxsaGFXVnFUQ1cydW5Y?oc=5","date":"2025-09-25","type":"pipeline","source":"The Business Journals","summary":"Momentive Performance Materials adds new member to C-suite - Albany Business Review - The Business Journals","headline":"Momentive Performance Materials adds new member to C-suite - Albany Business Review","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE11dlM3SVpoRnhhU05QbWwxQ3VmaGtqdjl1RnhyVS1uYmtLSmU3S0VHamZCaTR2eGk0T1JZMFFrZ1J3cllpVGN6MnV2bFQzVEExQ1ZleUFhUDB5ZmFzWDlCVTNadVRBbTBDdmpxZjVlNUI3cG8?oc=5","date":"2025-08-20","type":"pipeline","source":"Drug Store News","summary":"TSE Rewind: Camber Pharmaceuticals party - Drug Store News","headline":"TSE Rewind: Camber Pharmaceuticals party","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQcUVmd3FjaXNWWDZsTUxmbzgzUHlBTHc2QnZlT2czdlJYX1lMYjh4ekxmLXczOHdiN29YOWpqMkloNzVSeDVwWDVJbk1PNEVmQlJRdkFlR1V0ajRFWGVsVS1GTGwzeVVSNDVWWk1qZHJ3azB5NjJJeFBmMUlwSzlqeDFnMkFPX2ZFbEJsd0g2Qm1nUHVYNEVpal9yT2lQdmZlMGJkU2pjQQ?oc=5","date":"2025-06-30","type":"pipeline","source":"Cleanroom Technology","summary":"Catalent appoints Ricardo Pravda to lead human resources function - Cleanroom Technology","headline":"Catalent appoints Ricardo Pravda to lead human resources function","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOMGdKQ29VcTVVcENrNjVQdWo1RWRGMWdmLVRBTXd5SG10c2FSaXk2TnBOLUNPTmFNTGpIOVpoZTBfR1Vrek5EMWcwTnUxX3JsVUh1aHBzZWQ1S01POXVJMlJ6MTduNS1ZekFVR1BzaWxCbkZFNnl5MmNab2UxTjBXTXlnOTU2ZjQ3akE?oc=5","date":"2025-03-05","type":"pipeline","source":"Yahoo Finance","summary":"Rocket Pharmaceuticals, Inc. (RCKT): A Bull Case Theory - Yahoo Finance","headline":"Rocket Pharmaceuticals, Inc. (RCKT): A Bull Case Theory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxQTGVTYmh1Wm5OYjFnanRKYUtKbmJrUDI2QV91eGdvU1gyRGV2RlRjeGUyek9TekVKNlBrR25EeHZPSmR2bFktSXJMekw1WmlVWTNCbXRZNGRjekQtYmxUdEZNbkNiUm8tc0hRUFFWNmV6aTFoUWp3S2FqRU5WU21kSnNtb1Uyd0Z3LWwtN19FVl9qaUR2czJiZk85Qlg2cDBJRnpMaVBCaGFQd3dDZjNnb2VkLVRDT0hudjR5OXNSazk3ZFRXS0REZjZhRUR3bUM0MXBXMVVwaWtvVmFlaXVvVHlrVGNxYmZqTlVlOWhtSzBJOUpEdDF2Q0I0Z3RlcXJVc1J5T3lDY2J1Z2ozMWVCS0F3RE16cWdyUEsya0JreXpjZFE2TGl1amo2YlJWcElRdE5rWEdoZ1FNSmlyS3ZORA?oc=5","date":"2025-01-13","type":"trial","source":"GlobeNewswire","summary":"Myocardial Infarction Clinical Trial Pipeline Appears - GlobeNewswire","headline":"Myocardial Infarction Clinical Trial Pipeline Appears","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFBRNXI3dGFXbHFBS2hLcDdRVl9PRHRkNTRFODRyM2c2NXd2YnNBWWxSY043Mm5Fa1V0R0tMRnZPbVN4N2NMdjFfejBfOXVGRWI1bjh4QlUtVjdxTXVnZFY2Qg?oc=5","date":"2024-04-06","type":"pipeline","source":"JACC Journals","summary":"Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI - JACC Journals","headline":"Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOb19VdzlfRFkyQmh3a2VLa19ZODBqbmRTRWlkLWkzV1FMc0dHazFpNGpPZ3hDakNyNnZnbnR1TVUybkd6eHhaeUVVZ1Vxd2RVSTJBNVJtWkZ3MWFDTHFHbHd6SlVoU0FEblYyRzdtT3hJSHRNQ001bWI2VTdmNUc4UkowRF8xOHVzU25fcjJudm1yMTFSLXZBVHZqdGxOQ00?oc=5","date":"2022-06-01","type":"regulatory","source":"dicardiology.com","summary":"Recardio and FDA Reach Agreement on Pivotal Phase 3 Trial Design - dicardiology.com","headline":"Recardio and FDA Reach Agreement on Pivotal Phase 3 Trial Design","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_2":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}